Want to see EVO full AI Analyst Report?
EVO Stock Chart & Stats
$1.94
-$0.04(-2.02%)
At close: 4:00 PM EDT
$1.94
-$0.04(-2.02%)
Day’s Range― - ―
52-Week Range$1.90 - $4.27
Previous CloseN/A
Volume33.59K
Average Volume (3M)186.07K
Market Cap
$729.13M
Enterprise Value$1.01K
Total Cash (Recent Filing)$445.23M
Total Debt (Recent Filing)$387.87M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Nov 05, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding355,819,120
10 Day Avg. Volume383,647
30 Day Avg. Volume186,074
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.14
Price to Sales (P/S)1.23
P/FCF Ratio-11.82
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.80Price Target Upside44.33% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$687.28M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity PositionA large cash buffer (EUR ~445m) plus an expected ~USD100m inflow materially reduces short-term refinancing risk and funds the Horizon transformation. This strengthens the company's ability to invest in commercialization, absorb restructuring costs, and support partner programs over the next 2–6 months.
Proprietary Platforms & Co-owned PipelineProprietary discovery platforms and a large portfolio of co-owned assets create durable competitive advantages: recurring partnership demand, longer customer relationships and potential future milestone/royalty streams that provide optionality and strategic upside beyond fee-for-service revenue.
Improving Commercial Leading IndicatorsSustained improvement in proposals, faster turnaround and higher net orders indicate a strengthening sales funnel. If these trends persist, they should support higher contracted revenues and utilization over coming quarters, improving revenue visibility and helping margin recovery as Horizon actions take effect.
Bears Say
Declining Revenue & Weak MarginsSustained revenue declines and deeply negative margins reflect structural earnings weakness. Unless top-line stabilizes and higher-margin services scale, losses will persist, limiting the company's ability to generate durable profits in the 2–6 month horizon despite cost measures.
Negative Free Cash Flow And Volatile Cash GenerationNegative and volatile free cash flow constrains self-funded investment and increases reliance on asset sales, milestone receipts or external financing. This reduces resilience during transformation and could limit reinvestment in commercial growth or capacity even if operational indicators improve.
Large Restructuring Provisions & Execution RiskMaterial restructuring charges raise near-term cash outflows and execution risk: realizing targeted €75m run‑rate savings requires successful site consolidations and workforce changes, which can disrupt delivery and client relationships if not executed cleanly over the next several quarters.
Evotec AG News
EVO FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was $1.90 and its highest was $4.27 in the past 12 months.
What is Evotec AG’s market cap?
Evotec AG’s market cap is $729.13M.
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is Nov 05, 2026 which is in 82 days.
How were Evotec AG’s earnings last quarter?
Evotec AG released its earnings results on Aug 13, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.04 by -$0.11.
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG pays a Monthly dividend of $0.072 which represents an annual dividend yield of N/A. See more information on Evotec AG dividends here
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate is -0.27.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,819,120 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Evotec AG reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.04. Following the earnings report the stock price went down -7.763%.
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in EVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evotec AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.80 (44.33% Upside)
$2.80 (44.33% Upside)
Blogger Sentiment
Bullish
EVO Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.07%
Trailing 12-Months
Company Description
Evotec AG
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
EVO Company Deck
EVO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: near-term financials were weak with material revenue declines (H1 revenues down ~19%) and negative adjusted EBITDA (H1 EUR -42.7m), and management revised full-year 2026 guidance downward due mainly to timing shifts in strategic partnership milestone recognition. Offsetting these weaknesses are encouraging commercial leading indicators (inbound inquiries +~30%, proposals >45%, base D&PD net sales +~28% in H1), a healthy pipeline of 10–20 strategic partnership opportunities, strong liquidity (EUR 465.6m), active cost-savings via the Horizon program (~EUR 75m run-rate by 2027), and recent senior hires to improve commercial conversion. Overall, the issues appear driven largely by timing and phasing rather than loss of pipeline quality, but 2026 results and guidance remain meaningfully impacted.View all EVO earnings summariesEVO Stock 12 Month Forecast
Average Price Target
$2.80
▲(44.33% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.63% Other Institutional Investors
99.37% Public Companies and
Individual Investors